Oncology and Hematology

Episodes 1-16 of 323

• 

  RestartResume

  Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer

  RestartResume

  Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer

  MinuteCE®

  Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer

  1.25 program credits

  • 

    

    Wenxin Xu, MD

  • 

    

    Sandy Srinivas, MD

  1.25 program credits

• 

  RestartResume

  Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma

  RestartResume

  Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma

  MinuteCE®

  Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma

  1.25 program credits

  • 

    

    Wenxin Xu, MD

  • 

    

    Sandy Srinivas, MD

  1.25 program credits

• 

  RestartResume

  Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

  RestartResume

  Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

  MinuteCE®

  Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

  1.25 program credits

  • 

    

    Ignacio Duran, MD

  • 

    

    Sandy Srinivas, MD

  1.25 program credits

• 

  RestartResume

  Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances

  RestartResume

  Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances

  MinuteCE®

  Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  • 

    

    Nicoletta Colombo, MD

  1.00 program credit

• 

  RestartResume

  Testosterone Revisited: Importance of Monitoring and Impact of Rebound on Quality of Life in Advanced Prostate Cancer   

  RestartResume

  Testosterone Revisited: Importance of Monitoring and Impact of Rebound on Quality of Life in Advanced Prostate Cancer   

  MinuteCE®

  Testosterone Revisited: Importance of Monitoring and Impact of Rebound on Quality of Life in Advanced Prostate Cancer   

  0.75 program credits

  • 

    

    Tanya Dorff, MD

  0.75 program credits

• 

  RestartResume

  Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

  RestartResume

  Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

  MinuteCE®

  Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

  1.00 program credit

  • 

    

    Ritu Salani, MD, MBA

  • 

    

    Nicoletta Colombo, MD

  1.00 program credit

• 

  RestartResume

  Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer

  RestartResume

  Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer

  MinuteCE®

  Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  • 

    

    Ritu Salani, MD, MBA

  1.00 program credit

• 

  RestartResume

  Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences   

  RestartResume

  Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences   

  MinuteCE®

  Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences   

  0.75 program credits

  • 

    

    Rana McKay, MD

  0.75 program credits

• 

  RestartResume

  Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer

  RestartResume

  Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer

  MinuteCE®

  Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer

  1.00 program credit

  • 

    

    Ritu Salani, MD, MBA

  • 

    

    Nicoletta Colombo, MD

  1.00 program credit

• 

  RestartResume

  First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer

  RestartResume

  First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer

  MinuteCE®

  First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer

  1.00 program credit

  • 

    

    Nicoletta Colombo, MD

  • 

    

    Ritu Salani, MD, MBA

  1.00 program credit

• 

  RestartResume

  Understanding Bone Metastases in Breast Cancer: Impacts and Treatment Approaches

  RestartResume

  Understanding Bone Metastases in Breast Cancer: Impacts and Treatment Approaches

  Project Oncology®

  Understanding Bone Metastases in Breast Cancer: Impacts and Treatment Approaches

  • 

    

    Rachelle W. Johnson, PhD

• 

  RestartResume

  Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer

  RestartResume

  Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer

  MinuteCE®

  Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer

  1.00 program credit

  • 

    

    Nicoletta Colombo, MD

  • 

    

    Susana Campos, MD, MPH

  1.00 program credit

• 

  RestartResume

  Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

  RestartResume

  Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

  MinuteCE®

  Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  1.00 program credit

• 

  RestartResume

  Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer

  RestartResume

  Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer

  MinuteCE®

  Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer

  0.75 program credits

  • 

    

    Rana McKay, MD

  0.75 program credits

• 

  MinuteCE®

  Innovations in Oncology Learning Center From Guidelines to Practice: Genitourinary Cancers

  1.25 credits 10 episodes

  • 

    

    Ignacio Duran, MD

  • 

    

    Wenxin Xu, MD

  • 

    

    Sandy Srinivas, MD

  1.25 credits 10 episodes

• 

  RestartResume

  Selecting Patients for Novel Breast Cancer Imaging Modalities: The Role of AI

  RestartResume

  Selecting Patients for Novel Breast Cancer Imaging Modalities: The Role of AI

  Project Oncology®

  Selecting Patients for Novel Breast Cancer Imaging Modalities: The Role of AI

  • 

    

    Constance Lehman

• Prev
• 1
• 2
• 3
• …
• 20
• 21
• Next